Table 3.
Relationships between each parameter and the prevalence of SNL.
| Parameter | Grade | n | Median survival time (years) | 95% CI | P-value |
|---|---|---|---|---|---|
| Fibrosis | 1 | 16 | NA | 1.10-NA | .03* |
| 2 | 21 | 0.73 | .42-1.36 | ||
| 3 | 10 | 1.38 | .21-6.06 | ||
| BDP | 1 | 11 | NA | 1.09-NA | .08 |
| 2 | 17 | 1.27 | 0.44-NA | ||
| 3 | 10 | 0.73 | .35-5.14 | ||
| Cholestasis | 0 | 0 | NA | NA | .90 |
| 1 | 9 | 1.09 | 0.46-NA | ||
| 2 | 18 | 1.36 | 0.56-NA | ||
| 3 | 17 | 1.32 | .35-10.04 | ||
| DPM | 0 | 31 | 1.49 | 0.66–NA | .30 |
| 1 | 16 | 1.12 | .35-7.26 | ||
| ICI | 1 | 17 | 1.49 | 0.43-10.04 | .32 |
| 2 | 21 | 1.36 | 0.56-NA | ||
| 3 | 9 | 0.67 | 0.27-NA | ||
| CD3 | 1 | 11 | NA | 0.56–NA | .08 |
| 2 | 21 | 1.20 | .40-5.14 | ||
| 3 | 15 | 1.03 | 0.53-NA | ||
| CD20 | 1 | 18 | 0.71 | 0.35-1.23 | .01* |
| 2 | 17 | 1.49 | .66-10.04 | ||
| 3 | 12 | NA | 0.50-NA | ||
| HLA II-DR | 1 | 13 | 1.20 | 0.27-NA | .81 |
| 2 | 18 | 1.42 | 0.87-NA | ||
| 3 | 16 | 1.24 | 0.50-NA | ||
| α-SMA | 1 | 14 | NA | 1.09-NA | .04* |
| 2 | 10 | 1.11 | .33-7.26 | ||
| 3 | 23 | 0.73 | .43-1.49 |
Abbreviations: CI, confidence interval.
*Significant difference.
We evaluated the relationships of the grades of liver fibrosis, BDP, cholestasis, DPM, ICI, CD3, CD20, HLA II-DR, and α-SMA expression with the prevalence of SNL using the log-rank test. There were negative relationships for liver fibrosis and α-SMA, and a positive relationship for CD20.